Published on
Dec 18, 2024
CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo
Introduction As early as 2012, researchers from CUMC (Columbia University Medical Center) found that 3% of patients with glioblastoma had the FGFR3-TACC3 fusion gene.1 In 2018, this same group discovered that FGFR3-TACC3 causes the overactivation of …
Source:
Dove Medical Press
-
Neutral
